Advances in non-dopaminergic treatments for Parkinson's disease
about
Gene therapy: progress and predictionsUnmet needs of patients with narcolepsy: perspectives on emerging treatment optionsPharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical CorrelatesActivin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's diseaseNucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's diseaseDopamine signaling promotes the xenobiotic stress response and protein homeostasisCurrent Experimental Studies of Gene Therapy in Parkinson's DiseaseRole of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases.Dopaminergic Neurons Respond to Iron-Induced Oxidative Stress by Modulating Lipid Acylation and Deacylation Cycles.Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Effects of Postnatal Enriched Environment in a Model of Parkinson's Disease in Adult Rats.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Nondopaminergic treatments for Parkinson's disease: current and future prospects.Dopamine helps worms deal with stress.Verapamil Blocks Scopolamine Enhancement Effect on Memory Consolidation in Passive Avoidance Task in Rats.The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing.Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease.Neurochemical and Behavior Deficits in Rats with Iron and Rotenone Co-treatment: Role of Redox Imbalance and Neuroprotection by Biochanin A.Adenosine A2a Receptor Blockade Diminishes Wnt/β-Catenin Signaling in a Murine Model of Bleomycin-Induced Dermal Fibrosis.
P2860
Q26772109-B493E574-D607-4749-A2D9-468FD2A765DDQ26827736-99D4EDCA-9772-469D-B0F7-73C81E0C03BDQ26852311-AF2683D7-326A-434C-B951-1320E615F1A1Q27309140-7ACE1D42-B3BE-4EE9-948E-318CCAC031A1Q28085513-2B04585E-9109-44D7-99C4-90131C6CE830Q28388147-54304EF0-966E-4158-98BF-4E4EB7DB96BCQ33627771-614959EA-9EB1-4264-9886-5E40F474EE71Q34014053-C7B428D6-85A1-49E8-ADB0-BA9378655FEFQ35664174-8A026371-044A-4127-A982-962FD493901DQ36744366-07A0C736-AF08-4A06-A067-76AF49891BB5Q37690964-BCD26A14-3DCD-49D3-8D9D-7B705D57480EQ38658203-79A3ECE1-5B6B-4BAB-9BFF-B8911B1D0FF7Q38845546-CDA64F62-ACF8-4588-9EEC-2C65D9CBFEC3Q40991354-41577A56-9700-46E1-BBB4-60A136FB428DQ41527014-31FB8C56-3704-443D-A480-1A533BC5CCA2Q43170816-34D5B714-5CFA-4899-9696-63B46729C9B0Q46147033-EB862FEC-994A-4B8A-963F-C220E025858FQ47098715-088AC8AD-0858-444A-B1BE-67547DE8BEA0Q50197688-7CA1DC87-32CF-49BF-946C-7B1AB9BC14AE
P2860
Advances in non-dopaminergic treatments for Parkinson's disease
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Advances in non-dopaminergic treatments for Parkinson's disease
@en
type
label
Advances in non-dopaminergic treatments for Parkinson's disease
@en
prefLabel
Advances in non-dopaminergic treatments for Parkinson's disease
@en
P2860
P356
P1476
Advances in non-dopaminergic treatments for Parkinson's disease
@en
P2093
Bryce Vissel
Sandy Stayte
P2860
P356
10.3389/FNINS.2014.00113
P577
2014-05-22T00:00:00Z